Thyroid Cancer

The Food and Drug Administration has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options, according to a statement from Loxo Oncology, the developer of the selective RET inhibitor.

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.

From genetic mutations to treatment behind bars, here's a roundup of our 2018 Summer issue.

In this week’s episode of CURE Talks Cancer, we spoke with Voigt about how he noticed a lump in a woman’s neck while watching tv and utilized the power of social media to find her – which ultimately led to a thyroid cancer diagnosis.

Instead of undergoing surgery for potential cancer, many people with thyroid nodules can safely opt for surveillance.

High blood pressure is common in patients with thyroid cancer who are taking Lenvima. Here's what one expert says about managing it.

Cancer survivors worry about recurrence, but seldom think about their risk for new primaries.

The Food and Drug Administration (FDA) approved the two-drug combination Tafinlar (dabrafenib) and Mekinist (trametinib) to treat patients with metastatic or unresectable anaplastic thyroid cancer (ATC), whose tumors harbor the BRAF V600E mutation.

After being diagnosed with a rare cancer, professional runner Gabriele Grunewald became inspired to start a nonprofit that raised awareness for other rare cancers and empowered those who have them.

Tests like these are growing increasingly important, as TOO results lead to treatment changes about 65 percent of the time and a site treatment change about 35 percent of the time, according to Cancer Genetics.